Vaxine is a leading biotechnology company at the forefront of vaccine science, founded by Professor Nikolai Petrovsky. Despite its compact size, Vaxine has been making remarkable global impact in the field. The company believes that the quality of the underlying science and the ability to efficiently translate that science into human products are key factors for success, rather than company size.

Vaxine has achieved numerous world-firsts, surpassing even the largest and best-resourced pharmaceutical companies. These accomplishments include developing the first swine flu pandemic vaccine in 2009, the first AI-designed vaccine in 2019, and the first approved recombinant spike protein vaccine in 2021. While achieving these milestones, Vaxine remains dedicated to its core scientific mission of advancing knowledge and supporting cutting-edge research, with an impressive yearly publication record of 15-20 scientific research papers.

With over 20 years of experience, Vaxine has built an extensive portfolio of vaccines and immunotherapies for various diseases, including Covid-19, influenza, hepatitis B, Japanese encephalitis, allergy, and cancer. The company's success lies in its powerful vaccine adjuvant technology and its expertise in applying artificial intelligence to rapid drug design. Join the conversation and be part of Vaxine's journey towards groundbreaking advancements in vaccine science.

Contact Vaxine today to collaborate or learn more about their innovative projects and publications